Introduction
Every regulatory affairs career eventually raises the same question for people who are good at the work and want to keep growing: how far can this actually go? For most, the answer tops out at Director or Vice President of Regulatory Affairs, which is already a substantial, well-compensated destination. For a smaller group, the ambition extends further, to Chief Regulatory Officer, a genuine C-suite seat with a direct line to the CEO and a board-level voice in company strategy. That role exists at a meaningful number of pharmaceutical, biotech, and medical device companies, but the path to it is neither obvious nor well marked, and a lot of capable regulatory professionals plateau below it without ever understanding exactly why.
This is not a guide to becoming a better Head of Regulatory Affairs, a role this site has covered elsewhere. It is about the specific, and different, set of moves and capabilities that separate a strong regulatory executive from someone who actually reaches the C-suite.
What a Chief Regulatory Officer Actually Is, and Isn't
Not every company with a large regulatory function has a Chief Regulatory Officer. Many organizations top out at VP or Head of Regulatory Affairs, a senior functional leader who reports to the Chief Development Officer, Chief Medical Officer, or CEO but does not hold a formal C-suite title. A true CRO title, distinct from the clinical research organization acronym of the same letters, tends to appear at larger public companies, or at companies where regulatory strategy is so central to the business model, gene therapy, novel device categories, complex combination products, that the board wants a dedicated executive voice on it.
The functional difference matters more than the title itself. A VP of Regulatory Affairs typically owns submission strategy and agency relationships for the current pipeline. A Chief Regulatory Officer is expected to shape corporate strategy itself: which programs the company pursues, how it structures deals and partnerships, what risks it is willing to take with the board and investors, and how it represents the company's regulatory position externally to shareholders, potential acquirers, and industry bodies. The scope shifts from executing regulatory strategy well to setting the conditions under which the whole company thinks about regulatory risk.
It is also worth being honest that not every regulatory career should be aimed at this title, and that is a perfectly reasonable conclusion to reach. A VP or Head of Regulatory Affairs role can be a genuinely final destination that offers substantial scope, compensation, and influence without the additional demands, travel, and public accountability that come with a formal C-suite seat. The point of understanding the path clearly is not that everyone should walk it, but that professionals who do want it should understand what actually separates the two levels, rather than assuming the difference is simply time served.
The Experience That Actually Builds the Case
People who reach this level almost always share a few experiences, even though their specific career paths vary considerably.
- Multiple full product lifecycles. Not just one successful approval, but enough submissions, across different program types and outcomes, including at least one significant setback, to have built real judgment about how regulatory risk actually plays out rather than how it looks on paper.
- Direct board and investor exposure. Presenting regulatory strategy and risk to a board, to potential acquirers during diligence, or to investors ahead of a funding round is a distinct skill from presenting to FDA or internal leadership, and it is one that most regulatory professionals never get real practice at until someone hands them the opportunity.
- Cross-functional P&L exposure. Time spent close to commercial strategy, business development, or portfolio decisions, not owning those functions, but sitting close enough to understand how regulatory considerations actually trade off against commercial and financial ones.
- A track record of being right about hard calls. The professionals who get tapped for CRO roles are usually known, within their networks, for having called a difficult regulatory situation correctly when the easier or more optimistic read was tempting. That reputation compounds over a career and is hard to manufacture quickly.
The Moves That Tend to Matter
Few people walk a straight line from Regulatory Affairs Associate to Chief Regulatory Officer at the same company. Most paths include at least one of a few deliberate moves. A period in regulatory strategy consulting, or at a smaller, higher-risk company, tends to compress exposure to hard decisions faster than staying at a single large, process-heavy organization. Some form of business development, alliance management, or corporate strategy rotation, even a relatively brief one, gives regulatory leaders fluency in how the rest of the executive team actually thinks and talks, which becomes essential once they are sitting at that table permanently.
A move into a smaller or earlier-stage company as the most senior regulatory voice, even without a formal C-suite title yet, is one of the more common accelerants. Being the person a 40-person biotech relies on for regulatory judgment, with no layer of more senior regulatory leadership above, forces a kind of ownership and visibility that is harder to build inside a large, well-staffed regulatory department at a bigger company.
What Boards and CEOs Actually Look For
Technical regulatory expertise is table stakes at this level; almost everyone being seriously considered for a CRO role has it. What differentiates candidates is the ability to communicate regulatory risk in business terms a board can act on, rather than in the language of submission timelines and agency correspondence. A CEO evaluating a CRO candidate is really asking whether this person can walk into a board meeting and give a clear, honest, decision-ready answer to "what happens if this program doesn't get approved," without either sugarcoating the risk or burying the board in technical caveats that dodge the actual question.
Boards also weigh external credibility heavily: relationships with regulators, visibility within industry associations like RAPS or DIA, and a reputation that extends beyond a single company. That external profile is one of the more overlooked parts of building toward this role, and it does not happen by accident. It requires deliberate investment in professional visibility well before anyone is a formal candidate for a C-suite seat.
How the Role Differs Across Company Types
The Chief Regulatory Officer job looks meaningfully different depending on the kind of company. At a large, established pharmaceutical company, the role is often more about governance and portfolio-level risk management across dozens of programs simultaneously, with a large regulatory organization reporting up through the CRO and a heavier emphasis on consistency, process, and managing regulatory relationships across many simultaneous submissions and markets. At a smaller biotech with one or two lead programs, the CRO is closer to the actual submission work, often still personally involved in agency meetings and strategy for the company's core pipeline, with the C-suite dimension of the job centered more on investor and board communication than on managing a large internal team.
Medical device companies present a further variation, where the CRO role frequently also carries quality system oversight, given how tightly regulatory and quality functions are intertwined in device organizations. A candidate coming from a pure pharmaceutical regulatory background may need to build genuine fluency in quality systems and ISO standards before being a credible candidate for a device-company CRO seat, and the reverse is true for device-side leaders moving toward a pharmaceutical or biologics-heavy organization.
What to Do If You're Several Years Out
For regulatory professionals who are realistically five to ten years from being a credible CRO candidate, the most useful thing to do now is audit which of the experiences described above are missing and go find them deliberately, rather than assuming tenure alone will eventually supply them. That might mean volunteering for a board presentation opportunity even when it is not formally part of the job, raising a hand for involvement in a licensing deal or acquisition diligence process, or taking a lateral move to a smaller company specifically to get earlier, broader ownership. It also means building an external professional profile deliberately: publishing, speaking at industry conferences, and staying visible within professional associations, rather than assuming strong internal performance alone will eventually surface the opportunity. Executive recruiters searching for CRO candidates tend to start from people who are already visible in the field, which makes that visibility a practical career investment rather than an optional extra.
Conclusion
The path to Chief Regulatory Officer is not a natural extension of being an excellent Head of Regulatory Affairs, it requires a different set of experiences: board exposure, cross-functional fluency, external visibility, and a track record of judgment under real uncertainty, not just technical mastery of submissions and agency interactions. For regulatory professionals with genuine ambition toward the C-suite, the practical takeaway is to start deliberately seeking out the board exposure, the smaller-company ownership, and the cross-functional rotations well before a CRO search is actually underway, because those experiences are what separate the candidates a board will seriously consider from the much larger group of excellent regulatory leaders who never quite get the call.